LIXT

NASDAQ Healthcare

Lixte Biotechnology Holdings, Inc. - Common Stock

Biotechnology

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.

�� 市场数据
价格$7.04
成交量303,867
市值87.18M
贝塔系数1.050
RSI（14日）70.7 超买
200日均线$4.01
50日均线$4.14
52周最高$7.50
52周最低$0.64
Price / Book7.80
在Yahoo Finance查看 →
🎯 投资策略评分

LIXT 在各投资策略中的评分。分数越高，越符合该策略目标。

💰 Dividend Daddy 25/100
高股息率 + 低波动性
🚀 Moon Shot 35/100
高增长潜力（高贝塔 + 超卖）
🔪 Falling Knife 4/100
逆向投资（超卖 + 低于移动均线）
🎈 Over-Hyped 86/100
超买股票（潜在做空标的）
🐋 Institutional Whale 2/100
大盘、机构级别股票
🔍 策略解读

最佳匹配： 🎈 Over-Hyped (86/100) — 此策略 超买股票（潜在做空标的）.

评分最低的策略： 🐋 Institutional Whale (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →

📚 了解更多
本页指标
教育文章
网站资源
在文本中查找 LIXT in your text

粘贴任何文章、记录或帖子 — 工具将提取 LIXT 以及每一个其他隐藏的股票代码。

试试股票代码提取器 →

免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.